228 related articles for article (PubMed ID: 34656300)
21. Targeted axillary dissection with preoperative tattooing of biopsied positive axillary lymph nodes in breast cancer.
Gatek J; Petru V; Kosac P; Ratajsky M; Duben J; Dudesek B; Jancik P; Zabojnikova M; Katrusak J; Opelova P; Podrazska L; Vazan P; Kudlova P; Holik P; Melichar B; Vrana D
Neoplasma; 2020 Nov; 67(6):1329-1334. PubMed ID: 32749847
[TBL] [Abstract][Full Text] [Related]
22. [Axillary management in breast cancer: The French practice versus recommendations in the post-2011 era].
Clavier A; Cornou C; Capmas P; Bats AS; Bensaid C; Nos C; Lécuru F; Ngô C
J Gynecol Obstet Biol Reprod (Paris); 2016 May; 45(5):451-8. PubMed ID: 26989008
[TBL] [Abstract][Full Text] [Related]
23. The Influence of Hospital and Surgeon Factors on the Prevalence of Axillary Lymph Node Evaluation in Ductal Carcinoma In Situ.
Coromilas EJ; Wright JD; Huang Y; Feldman S; Neugut AI; Chen L; Hershman DL
JAMA Oncol; 2015 Jun; 1(3):323-32. PubMed ID: 26181180
[TBL] [Abstract][Full Text] [Related]
24. The prognostic value of sentinel lymph node micrometastases in patients with invasive breast carcinoma.
Cipolla C; Graceffa G; La Mendola R; Fricano S; Fricano M; Vieni S
Ann Ital Chir; 2015; 86():497-502. PubMed ID: 26898168
[TBL] [Abstract][Full Text] [Related]
25. Total Tumor Load of mRNA Cytokeratin 19 in the Sentinel Lymph Node as a Predictive Value of Axillary Lymphadenectomy in Patients with Neoadjuvant Breast Cancer.
Peña KB; Kepa A; Cochs A; Riu F; Parada D; Gumà J
Genes (Basel); 2021 Jan; 12(1):. PubMed ID: 33435629
[TBL] [Abstract][Full Text] [Related]
26. [Surgical treatment and prognosis of ductal carcinoma in situ: 526 cases analysis].
Zhu SJ; Chen XS; Wu JY; Huang O; He JR; Zhu L; Chen WG; Li YF; Fei XC; Shen KW
Zhonghua Wai Ke Za Zhi; 2017 Feb; 55(2):114-119. PubMed ID: 28162210
[No Abstract] [Full Text] [Related]
27. A N0 Predicting Model for Sentinel Lymph Node Biopsy Omission in Early Breast Cancer Upstaged From Ductal Carcinoma in Situ.
Yoo TK; Kim SJ; Lee J; Lee SB; Lee SJ; Park HY; Park HK; Chae BJ; Eom YH; Kim HS; Song BJ
Clin Breast Cancer; 2020 Jun; 20(3):e281-e289. PubMed ID: 32147404
[TBL] [Abstract][Full Text] [Related]
28. De-escalation of axillary surgery in early breast cancer.
Jatoi I; Benson JR; Toi M
Lancet Oncol; 2016 Oct; 17(10):e430-e441. PubMed ID: 27733269
[TBL] [Abstract][Full Text] [Related]
29. Sentinel lymph node mapping following neoadjuvant chemotherapy for breast cancer.
Brady EW
Breast J; 2002; 8(2):97-100. PubMed ID: 11896755
[TBL] [Abstract][Full Text] [Related]
30. Long-term morbidity of patients with early breast cancer after sentinel lymph node biopsy compared to axillary lymph node dissection.
Schulze T; Mucke J; Markwardt J; Schlag PM; Bembenek A
J Surg Oncol; 2006 Feb; 93(2):109-19. PubMed ID: 16425290
[TBL] [Abstract][Full Text] [Related]
31. Residual lymph node tumour burden following removal of a single axillary sentinel lymph with macrometastatic disease in women with screen-detected invasive breast cancer.
Dave RV; Cheung S; Sibbering M; Kearins O; Jenkins J; Gandhi A
BJS Open; 2021 Mar; 5(2):. PubMed ID: 33688940
[TBL] [Abstract][Full Text] [Related]
32. Factors Predictive of Sentinel Lymph Node Involvement in Primary Breast Cancer.
Malter W; Hellmich M; Badian M; Kirn V; Mallmann P; Krämer S
Anticancer Res; 2018 Jun; 38(6):3657-3662. PubMed ID: 29848724
[TBL] [Abstract][Full Text] [Related]
33. Radiotherapy of breast cancer.
Hennequin C; Belkacémi Y; Bourgier C; Cowen D; Cutuli B; Fourquet A; Hannoun-Lévi JM; Pasquier D; Racadot S; Rivera S
Cancer Radiother; 2022; 26(1-2):221-230. PubMed ID: 34955414
[TBL] [Abstract][Full Text] [Related]
34. Sentinel lymph node biopsy can be omitted in DCIS patients treated with breast conserving therapy.
van Roozendaal LM; Goorts B; Klinkert M; Keymeulen KBMI; De Vries B; Strobbe LJA; Wauters CAP; van Riet YE; Degreef E; Rutgers EJT; Wesseling J; Smidt ML
Breast Cancer Res Treat; 2016 Apr; 156(3):517-525. PubMed ID: 27083179
[TBL] [Abstract][Full Text] [Related]
35. Combined procedure of marking axillary positive node with iodine-125 seed and sentinel lymph node biopsy in breast cancer patients treated with neoadjuvant chemotherapy.
Custodio Rebollo Aguirre A; Sánchez Sánchez R; González Jiménez AD; Culiañez Casas M; Mendoza Arnau I; Rashki M; Rudolphi Solero T; Martínez Meca S
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(2):75-83. PubMed ID: 31759957
[TBL] [Abstract][Full Text] [Related]
36. De-escalation of Axillary Surgery in the Neoadjuvant Chemotherapy (NACT) Setting for Breast Cancer: Is it Oncologically Safe?
Wazir U; Mokbel K
Anticancer Res; 2020 Oct; 40(10):5351-5354. PubMed ID: 32988853
[TBL] [Abstract][Full Text] [Related]
37. Ductal carcinoma in situ: value of sentinel lymph node biopsy.
Sakr R; Barranger E; Antoine M; Prugnolle H; Daraï E; Uzan S
J Surg Oncol; 2006 Oct; 94(5):426-30. PubMed ID: 16967457
[TBL] [Abstract][Full Text] [Related]
38. Repeat sentinel lymph node biopsy in patients with ipsilateral recurrent breast cancer after breast-conserving therapy and negative sentinel lymph node biopsy: a prospective study.
Folli S; Falco G; Mingozzi M; Buggi F; Curcio A; Ferrari G; Taffurelli M; Regolo L; Nanni O
Minerva Chir; 2016 Apr; 71(2):73-9. PubMed ID: 26207566
[TBL] [Abstract][Full Text] [Related]
39. Time trends and inter-hospital variation in treatment and axillary staging of patients with ductal carcinoma in situ of the breast in the era of screening in Southern Netherlands.
van Steenbergen LN; Voogd AC; Roukema JA; Louwman WJ; Duijm LE; Coebergh JW; van de Poll-Franse LV
Breast; 2014 Feb; 23(1):63-8. PubMed ID: 24291376
[TBL] [Abstract][Full Text] [Related]
40. [Impact of omission of axillary dissection on adjuvant therapy in patients with metastatic sentinel lymph nodes according to the ACOSOG Z0011 criteria].
Roosen A; Lousquy R; Bricou A; Delpech Y; Selz J; Le Maignan C; Bousquet G; Winterman S; Zelek L; Barranger E
Gynecol Obstet Fertil; 2014 Jun; 42(6):409-14. PubMed ID: 24861437
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
